Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401423 | 0.88 | LMNA (0.43) | FABP4FABP5MEN1KMT2AALDH1A1 | |
| SCHEMBL15402604 | 0.87 | BCHE (0.38) | BCHEACHEFABP4FABP5MEN1 | |
| SCHEMBL15375542 | 0.87 | FABP4 (0.48) | BCHEACHEFABP4FABP5KMT2A | |
| SCHEMBL15401610 | 0.87 | BCHE (0.40) | BCHEACHEFABP4FABP5MEN1 | |
| SCHEMBL15375316 | 0.87 | BCHE (0.40) | BCHEACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL15375481 | 0.86 | FABP4 (0.37) | BCHEACHEFABP4FABP5MEN1 | |
| SCHEMBL15402278 | 0.83 | RAB9A (0.45) | MEN1KMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL15375528 | 0.81 | LPAR1 (0.42) | FABP4FABP5KMT2A | |
| SCHEMBL15403550 | 0.81 | FABP4 (0.43) | FABP4FABP5 | |
| SCHEMBL15402835 | 0.79 | MAPT (0.44) | FABP4FABP5MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| CN-103641731-B | The manufacture method of phenylacetyl amine compound | SUMITOMO CHEMICAL CO., LTD. (JP) | 2015-10-28 | — | — | CN | disclosed |
| CN-103588657-A | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL CO | 2014-02-19 | — | — | CN | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | BCHE 2680/4885ACHE 1848/4885FABP4 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.